Zacks Research Issues Pessimistic Outlook for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Equities researchers at Zacks Research reduced their Q2 2025 EPS estimates for Corcept Therapeutics in a research note issued on Monday, May 26th. Zacks Research analyst K. Das now anticipates that the biotechnology company will earn $0.23 per share for the quarter, down from their previous forecast of $0.37. The consensus estimate for Corcept Therapeutics' current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics' Q3 2025 earnings at $0.35 EPS, Q4 2025 earnings at $0.58 EPS, FY2025 earnings at $1.33 EPS, Q1 2026 earnings at $0.27 EPS, Q2 2026 earnings at $0.37 EPS, Q3 2026 earnings at $0.50 EPS, Q4 2026 earnings at $0.51 EPS, FY2026 earnings at $1.65 EPS, Q1 2027 earnings at $0.66 EPS and FY2027 earnings at $3.81 EPS.

A number of other equities analysts have also weighed in on CORT. HC Wainwright cut their target price on shares of Corcept Therapeutics from $150.00 to $145.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Piper Sandler raised their price objective on shares of Corcept Therapeutics from $128.00 to $131.00 and gave the company an "overweight" rating in a research report on Thursday, April 3rd. Wall Street Zen lowered shares of Corcept Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, May 14th. Truist Financial set a $135.00 price objective on shares of Corcept Therapeutics in a research report on Tuesday, May 6th. Finally, Canaccord Genuity Group raised their price objective on shares of Corcept Therapeutics from $130.00 to $142.00 and gave the company a "buy" rating in a research report on Tuesday, April 1st. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $138.25.

Corcept Therapeutics Stock Performance

NASDAQ CORT traded up $0.45 during trading hours on Thursday, reaching $78.09. 1,203,879 shares of the company were exchanged, compared to its average volume of 1,123,363. Corcept Therapeutics has a 1 year low of $28.04 and a 1 year high of $117.33. The business's 50 day simple moving average is $72.53 and its 200-day simple moving average is $63.28. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $8.28 billion, a P/E ratio of 61.98 and a beta of 0.22.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.17. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The business had revenue of $157.21 million during the quarter, compared to the consensus estimate of $177.93 million. During the same quarter last year, the company posted $0.25 earnings per share. The firm's quarterly revenue was up 7.1% compared to the same quarter last year.

Insider Activity at Corcept Therapeutics

In related news, insider Sean Maduck sold 18,303 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $60.69, for a total value of $1,110,809.07. Following the sale, the insider now directly owns 85,622 shares of the company's stock, valued at $5,196,399.18. This trade represents a 17.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Joseph Douglas Lyon sold 421 shares of the firm's stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $60.58, for a total transaction of $25,504.18. Following the completion of the sale, the insider now directly owns 9,009 shares in the company, valued at $545,765.22. This represents a 4.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 296,352 shares of company stock valued at $24,908,205 over the last three months. 20.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Strs Ohio bought a new stake in shares of Corcept Therapeutics in the 1st quarter worth approximately $1,531,000. Advisors Capital Management LLC bought a new stake in shares of Corcept Therapeutics in the 1st quarter worth approximately $251,000. Iron Gate Global Advisors LLC bought a new stake in shares of Corcept Therapeutics in the 1st quarter worth approximately $400,000. Acadian Asset Management LLC lifted its holdings in shares of Corcept Therapeutics by 45.4% in the 1st quarter. Acadian Asset Management LLC now owns 166,490 shares of the biotechnology company's stock worth $19,011,000 after acquiring an additional 52,000 shares during the last quarter. Finally, Intech Investment Management LLC lifted its holdings in shares of Corcept Therapeutics by 28.1% in the 1st quarter. Intech Investment Management LLC now owns 66,735 shares of the biotechnology company's stock worth $7,622,000 after acquiring an additional 14,628 shares during the last quarter. 93.61% of the stock is owned by hedge funds and other institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.